

Mohamad Mohty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1694614/publications.pdf>

Version: 2024-02-01

133
papers

5,275
citations

94269

37
h-index

106150

65
g-index

134
all docs

134
docs citations

134
times ranked

5485
citing authors

#	ARTICLE	IF	CITATIONS
1	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. <i>Haematologica</i> , 2022, 107, 1397-1409.	1.7	16
2	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 183-190.	1.3	12
3	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	0.6	13
4	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	3.3	39
5	Immune restoration therapy for multidrug-resistant CMV disease in an allogeneic stem cell transplant recipient. <i>Current Research in Translational Medicine</i> , 2022, 70, 103329.	1.2	2
6	Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	1
7	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	1.3	4
8	Editorial: Strengths and Challenges of Allo-SCT in the Modern Era. <i>Frontiers in Oncology</i> , 2022, 12, 850403.	1.3	1
9	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. <i>Bone Marrow Transplantation</i> , 2022, 57, 742-752.	1.3	45
10	Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. <i>Blood</i> , 2022, 139, 2666-2672.	0.6	12
11	Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin. <i>British Journal of Haematology</i> , 2022, , .	1.2	0
12	Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. <i>Blood Cancer Journal</i> , 2022, 12, 47.	2.8	19
13	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
14	How I treat triple-class refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 244-256.	1.2	9
15	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1116-1123.	1.3	5
16	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , the, 2022, 9, e374-e384.	2.2	11
17	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1260-1268.	1.3	1
18	Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	1.3	119
20	Additional cytogenetic features determine outcome in patients allografted for <i>TP53</i> mutant acute myeloid leukemia. <i>Cancer</i> , 2022, 128, 2922-2931.	2.0	17
21	Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 780-784.	1.2	1
22	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 4258-4266.	3.2	15
23	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	1.3	36
24	<i>del(17p)</i> without <i>TP53</i> mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , 2021, 137, 1192-1195.	0.6	48
25	Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 419-427.	0.6	9
26	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 1272-1280.	1.3	18
27	Combination of brentuximab vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma. <i>European Journal of Haematology</i> , 2021, 106, 467-472.	1.1	8
28	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 917-927.	1.3	8
29	Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. <i>American Journal of Hematology</i> , 2021, 96, 80-88.	2.0	17
30	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
31	One Year into the COVID-19 Pandemic. <i>Clinical Hematology International</i> , 2021, 3, 1.	0.7	2
32	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	2.5	56
33	How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic?. <i>Acta Haematologica</i> , 2021, 144, 500-507.	0.7	4
34	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. <i>Bone Marrow Transplantation</i> , 2021, 56, 1651-1664.	1.3	221
35	Thiotepa busulfan fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	1.3	8
36	Expert review on soft tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67

#	ARTICLE	IF	CITATIONS
37	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
38	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus autologous cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	1.2	17
39	Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective. <i>British Journal of Haematology</i> , 2021, 195, 495-506.	1.2	5
40	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	1.2	13
41	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 53.	6.9	51
42	Comprehensive Review of AL amyloidosis: some practical recommendations. <i>Blood Cancer Journal</i> , 2021, 11, 97.	2.8	37
43	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer cell lymphoma, nasal type: A French study from the Soci�t� Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGMTC). <i>American Journal of Hematology</i> , 2021, 96, 834-845.	2.0	5
44	A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2454-2463.	1.3	11
45	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021, 14, 84.	6.9	27
46	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , 2021, 397, 2361-2371.	6.3	177
47	A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 2477-2488.	1.3	8
48	Increasing Donor Options in Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 1951-1954.	0.8	1
49	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. <i>JACC: CardioOncology</i> , 2021, 3, 250-259.	1.7	48
50	Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies. <i>Blood Cancer Journal</i> , 2021, 11, 126.	2.8	22
51	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 831-840.	0.2	1
52	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1378-1390.	5.1	84
53	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received �3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.	0.6	1
54	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. <i>Blood</i> , 2021, 138, 2920-2920.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2. <i>Blood</i> , 2021, 138, 82-82.	0.6	10
56	Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1631-1631.	0.6	0
57	Hematopoietic Cell Transplant Consideration for Philadelphia Chromosome-“Like Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e16-e20.	2.0	18
58	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
59	Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 452-460.	1.3	12
60	Gut microbiota alteration during allogeneic haematopoietic cell transplantation: what can we do?. <i>British Journal of Haematology</i> , 2020, 188, 351-353.	1.2	2
61	Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?. <i>Bone Marrow Transplantation</i> , 2020, 55, 505-522.	1.3	19
62	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 763-772.	1.3	16
63	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
64	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 377-382.	0.2	10
65	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020, 26, 6475-6482.	3.2	40
66	Maintenance after allogeneic HSCT in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2020, 21, 1130-1132.	5.1	3
67	FLAMSA-Based Reduced-intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2165-2173.	2.0	17
68	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet</i> , The, 2020, 396, 1885-1894.	6.3	206
69	Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. <i>European Journal of Haematology</i> , 2020, 105, 308-325.	1.1	11
70	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020, 55, 2244-2253.	1.3	6
71	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020, 13, 46.	6.9	68
72	Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 42.	6.9	56

#	ARTICLE	IF	CITATIONS
73	Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. Bone Marrow Transplantation, 2020, 55, 2224-2233.	1.3	23
74	Acute lymphoblastic leukaemia. Lancet, The, 2020, 395, 1146-1162.	6.3	343
75	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. Current Research in Translational Medicine, 2020, 68, 111-118.	1.2	30
76	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	1.7	91
77	Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other. Clinical Hematology International, 2020, 2, 41.	0.7	1
78	Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better. Clinical Hematology International, 2020, 2, 92.	0.7	2
79	Looking Ahead: Clinical Hematology International Turns One. Clinical Hematology International, 2020, 2, 1.	0.7	1
80	Prevention and treatment of relapse after stem cell transplantation by cellular therapies. Bone Marrow Transplantation, 2019, 54, 26-34.	1.3	14
81	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2019, 54, 519-530.	1.3	54
82	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
83	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2366-2374.	2.0	3
84	Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia, 2019, 33, 2127-2143.	3.3	36
85	Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process. TH Open, 2019, 03, e340-e347.	0.7	6
86	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
87	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. European Journal of Haematology, 2019, 103, 107-115.	1.1	23
88	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2019, 186, 767-776.	1.2	31
89	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	1.3	86
90	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2019, 54, 1815-1826.	1.3	75

#	ARTICLE	IF	CITATIONS
91	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1407-1415.	2.0	42
92	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	1.3	129
93	Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. <i>Advances in Hematology</i> , 2019, 2019, 1-12.	0.6	9
94	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 88.	2.8	39
95	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	2.0	15
96	Haploidentical <i>versus</i> unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2019, 104, 524-532.	1.7	68
97	Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 734-742.	2.0	17
98	Clinical Hematology International: Why a New Journal in Hematology?. <i>Clinical Hematology International</i> , 2019, 1, 1.	0.7	0
99	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
100	Tâ€œcellâ€œ-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). <i>Cancer</i> , 2018, 124, 2142-2150.	2.0	8
101	Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1471-1475.	2.0	28
102	Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 859-866.	2.0	28
103	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1013-1021.	2.0	59
104	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 431-437.	1.3	37
105	Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 113-124.	1.3	27
106	Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. <i>Blood</i> , 2018, 132, 750-754.	0.6	44
107	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	3.4	97
108	Validation of the acute leukemiaâ€œEBMT score for prediction of mortality following allogeneic stem cell transplantation in a multiâ€œcenter GITMO cohort. <i>American Journal of Hematology</i> , 2017, 92, 429-434.	2.0	33

#	ARTICLE	IF	CITATIONS
109	Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 2867-2874.	2.0	100
110	Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. <i>American Journal of Hematology</i> , 2017, 92, 1318-1323.	2.0	21
111	Evaluation of Infectious Complications after Haploidentical Stem Cell Transplantation in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2017, 130, 664-664.	0.6	3
112	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2017, 130, 852-852.	0.6	0
113	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 2941-2951.	2.0	140
114	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	2.0	31
115	Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. <i>Blood</i> , 2016, 127, 3450-3457.	0.6	86
116	Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. <i>Haematologica</i> , 2016, 101, e352-e354.	1.7	49
117	Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). <i>Leukemia and Lymphoma</i> , 2016, 57, 2937-2941.	0.6	1
118	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. <i>American Journal of Hematology</i> , 2016, 91, 366-370.	2.0	110
119	High CD34+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncotarget</i> , 2016, 7, 27255-27266.	0.8	53
120	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. <i>Haematologica</i> , 2015, 100, 558-564.	1.7	29
121	A bit of sweetness for GVHD prevention. <i>Blood</i> , 2015, 125, 1364-1365.	0.6	1
122	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. <i>Haematologica</i> , 2015, 100, 269-274.	1.7	28
123	Effect of Graft Source on Unrelated Donor Hemopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia after Reduced-Intensity or Nonmyeloablative Conditioning: A Study from the Soci�t� Francaise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1059-1067.	2.0	24
124	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2015, 100, 859-869.	1.7	80
125	Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. <i>Cancer</i> , 2015, 121, 562-569.	2.0	28
126	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3211-3211.	0.6	3

#	ARTICLE	IF	CITATIONS
127	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <i>Haematologica</i> , 2014, 99, 1486-1491.	1.7	25
128	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1380-1386.	1.7	31
129	Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. <i>European Journal of Cancer</i> , 2014, 50, 411-417.	1.3	60
130	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. <i>Blood</i> , 2014, 124, 681-681.	0.6	0
131	Impact of Antithymocyte Globulins on Patient Outcome after Myeloablative Bone Marrow Stem Cell Transplantation from HLA 10/10-Matched Unrelated Donor: A Report from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). <i>Blood</i> , 2014, 124, 1218-1218.	0.6	0
132	Immunobiology and Pharmacologic Manipulation of Dendritic and Regulatory Cells. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-2.	3.3	3
133	Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci�t� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM�TC). <i>British Journal of Haematology</i> , 2011, 152, 331-339.	1.2	104